“Right now, we are assuming that the patent will be lost in 2028.”

In context

“ides, including an ultra-long GLP-1 that's potentially three-monthly quarterly. That's currently in phase one. As well as our additional oral portfolio, including the oral GLP-1 recently acquired from Yopharma. Albert Bourla: Thank you, Chris. Next question, please. Operator: Our next question comes from Steve Scala with TD Cowen. Please go ahead. Steve Scala: In the VSPRS three data, did the placebo arm gain weight or lose weight? And the second question is not on obesity, but Pfizer Inc. has been quite adamant about no life beyond December 28 for Vyndaqal. Should we completely rule out any sort of strategy whatsoever such as settlement with generic companies on patents, Pfizer Inc. holds? Albert Bourla: Thank you, Steve. Let me take the Vyndaqal because I have been asked multiple times. Right now, we are assuming that the patent will be lost in 2028. And I don't have any other comments to make on that. You know these are very sensitive topics. So I'm moving to Chris now to talk about the placebo arm. Oh, the placebo arm. What was the weight loss there? Chris Boshoff: Oh, and again, the full data we presented ADA, but in this case, VESPA three, actually, the placebo arm was very stable, not really up or down, but you'll see the data at ADA. Albert Bourla: Alright. Thank you very much. The next question, please. Operator: Our next question comes from Geoffrey Meacham with Citibank. Please go ahead. Geoffrey Meacham: Congrats on the data today. Again, a few on the new data today. So you look at the PKPD, are you guys set with monthly being the longest dosing interval to preserve efficacy? Or is it potentially is it feasible to extend to,”